Results 71 to 80 of about 4,816,902 (277)

A Deep Generative Model Enables Automated Structure Elucidation of Novel Psychoactive Substances [PDF]

open access: yes, 2021
Over the past decade, the illicit drug market has been reshaped by the proliferation of clandestinely produced designer drugs. These agents, referred to as new psychoactive substances (NPSs), are designed to mimic the physiological actions of better ...
Russell, Greiner   +6 more
core   +1 more source

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg   +7 more
wiley   +1 more source

Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari   +2 more
wiley   +1 more source

New psychoactive substances in Poland. The analysis of policy responses and its effects

open access: yes, 2017
Introduction : The aim of this article is to analyse the process of creation and implementation of policy on new psychoactive substances (NPS) in Poland in the context of definitional and legal issues, social and market response, implementation of ...
Michał Bujalski   +2 more
core   +1 more source

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen   +7 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou   +3 more
wiley   +1 more source

An ETH‐LAD trip with unfavourable consequences: A case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler   +6 more
wiley   +1 more source

The impact of pharmacogenetic‐informed care on medication adherence and psychological factors associated with adherence: A narrative review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Improvement in medication adherence is often proposed as a potential advantage of pharmacogenetic‐guided prescribing over a traditional one‐size‐fits‐all approach. This paper provides a review of the published literature and presents the findings of studies that measure adherence to medication as an outcome of pharmacogenetic‐informed care, or that ...
Lucy Galloway   +2 more
wiley   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor   +11 more
wiley   +1 more source

Experiences of Prisoners Living With Mental Health Conditions and Seeking or Receiving Mental Health Support in Prisons: An Integrative Review

open access: yesCriminal Behaviour and Mental Health, EarlyView.
ABSTRACT Background Prisoners experience poor mental health and well‐being in prison, including severe mental illnesses. However, access to mental health support and treatment in prison is limited. We conducted an integrative review to synthesise prisoners' experiences of living with mental ill health and/or seeking or receiving mental health support ...
Anne Kairu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy